The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for revolutionary treatments and significant returns is undeniable, the linked risks are also consi